SMW Free Realtime Trade Alerts -- Fast Moving Stocks < $15 -- Join Today for FREE!!

Halozyme Therapeutics, Inc.
(NASDAQ : HALO)

( )
HALO After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
Loading HALO News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-1.41%77.861.1%$762.01m
SRPTSarepta Therapeutics, Inc.
-2.02%60.9827.0%$472.15m
AMGNAmgen Inc.
-2.51%165.451.2%$466.13m
BIIBBiogen Inc.
-1.54%305.781.1%$421.73m
CELGCelgene Corporation
-2.89%102.770.9%$388.33m
MDVNMedivation, Inc.
0.05%81.481.9%$386.22m
REGNRegeneron Pharmaceuticals, Inc.
-3.04%406.363.7%$307.31m
CPHDCepheid
0.08%52.735.5%$217.23m
ALXNAlexion Pharmaceuticals, Inc.
-2.99%120.062.2%$174.86m
CLVSClovis Oncology, Inc.
-4.68%34.6428.4%$157.24m
ILMNIllumina, Inc.
-2.44%176.563.4%$139.66m
VRTXVertex Pharmaceuticals Incorporated
-4.32%85.002.3%$129.21m
INCYIncyte Corporation
-0.96%92.312.8%$127.69m
BMRNBioMarin Pharmaceutical Inc.
-3.38%92.784.0%$111.66m
TSROTESARO, Inc.
-3.68%100.5817.5%$111.58m

Company Profile

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel oncology therapies that target the tumor microenvironment. Its investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor. PEGPH20 is currently in development for metastatic pancreatic cancer and non-small cell lung cancer and has potential across additional cancers in combination with different types of cancer therapies. Halozyme Therapeutics was founded by Gregory Ian Frost in 1998 and is headquartered in San Diego, CA.